Amevive: Welcome to Amevive.com

ABOUT AMEVIVE

Text Size

Amevive® (alefacept) was the first biologic agent approved for treating moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.[1] Its dual mechanism of action both prevents activation of pathogenic T cells and reduces their population.[1,2] In clinical trials, Amevive provided significant improvements in plaque psoriasis and extended breaks from treatment.[1,3] Additionally, Amevive provided an established safety and tolerability profile.[1]

How does Amevive work? Amevive is the only biologic that uses the body's natural killer cells to trigger apoptosis of pathogenic T cells.[1]		How Amevive is dosed Amevive is administered once weekly for 12 weeks and is followed by at least 12 weeks off treatment.[1]
Read More		Read More
Amevive provides increasing efficacy with an additional course A clinical study showed that, with 1 course of Amevive, 21% of patients achieved PASI 75 reductions at week 14 vs 5% with placebo; a greater proportion of patients achieved PASI 75 reductions with 2 courses.[1-4]		Amevive has an established safety and tolerability profile In clinical trials, rates of serious adverse events were low and did not increase with additional courses of Amevive.[5] Read More
Read More

Treatment Considerations

The most serious adverse reactions in clinical trials were lymphopenia, malignancies, serious infections requiring hospitalization, and hypersensitivity reactions.

Amevive should not be administered to patients infected with HIV, with a history of systemic malignancy, clinically important infection, known hypersensitivity to Amevive or any of its components, or to patients receiving other immunosuppressive agents or phototherapy.

Please see important safety information and accompanying full prescribing information.

REFERENCES:

Amevive® (alefacept) prescribing information, Astellas Pharma US, Inc.
Lebwohl M, Christophers E, Langley R, et al. Arch Dermatol. 2003;139:719-727.
Data on file, Astellas Pharma US, Inc.
Gordon KB, Langley RG. J Drugs Dermatol. 2003;2:624-628.
Goffe B, Papp K, Gratton D, et al. Clin Ther. 2005;27:1912-1921.